Scientia Advisors Names Randy Goodman Manager of Pricing and Market Access Group

Health economics, policy & reimbursement expert to help healthcare, diagnostics, biotech, medical device, health IT and pharma companies bring products to market

Scientia Advisors Names Randy Goodman Manager of Pricing and Market Access Group

Scientia AdvisorsGretchen Hamilton, 617-299-3051

Randy Goodman, PhD, a nationally recognized expert in pricing, reimbursement and managed care, has joined global strategy firm Scientia Advisors as manager of the firm’s Pricing and Market Access Group, Scientia Advisors announced, today.

Scientia Advisors is a global management consulting firm specializing in strategy, operations and pricing/reimbursement for major and emerging companies in healthcare, life sciences, pharma, biotechnology, and health IT. The firm’s Pricing and Market Access Group helps companies determine how best to introduce and develop pricing structures, and obtain reimbursement from third-party payers--within a context of highly competitive industries and rapidly changing health and regulatory systems, worldwide.

“Dr. Goodman comes to Scientia with a wealth of experience in the managed care, medical device, and biotech industries,” said Harry Glorikian, Scientia Advisors’ founder and managing partner. “He has directed pricing, reimbursement and managed markets strategies for a variety of US and global healthcare and device companies and has served as a consultant to the White House on health reform. We are delighted to welcome him to our firm.”

Immediately before joining Scientia, Dr. Goodman was Consultant/Director of health economics, reimbursement, managed markets and government relations for Welldoc, Inc., a leading provider of mobile health diabetes solutions in the US.

Previously, he served in a similar capacity for medical device/equipment companies ImpediMed, Inc., in San Diego; Access Mediquip, LLC, in Houston; and Hoveround,Corporation, in Sarasota. At various times, he has overseen and managed strategic development, clinical reimbursement policy, regulation and financial analysis, business development, sales and marketing, among other duties.

Dr. Goodman served as a Health Care Reform Policy Consultant to the White House Office of Health Reform in 2009 and 2010 and counseled and collaborated with the White House and Congress on health reform proposals in 1992 and 1993.

He holds a PhD in Health Policy and Master of Health Administration from Harvard University and a BA from the University of Texas. He is a fellow in the American College of Healthcare Executives, a Director of the National Association of Specialty Health Organization, among other affiliations.

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.